Literature DB >> 30935661

Activated Protein C for Ischemic Central Retinal Vein Occlusion: One-Year Results.

Chikako Hara1, Motohiro Kamei2, Hirokazu Sakaguchi1, Nagakazu Matsumura1, Susumu Sakimoto1, Mihoko Suzuki1, Kentaro Nishida1, Yoko Fukushima1, Kohji Nishida1.   

Abstract

Intravitreally administered activated protein C in 10 eyes with ischemic central retinal vein occlusion significantly improved macular edema; in 5 eyes, the reperfusion of the retinal nonperfused areas exceeded 50% of baseline.
Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2018        PMID： 30935661     DOI： 10.1016/j.oret.2018.07.012

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN： 2468-6530


  2 in total

1.  Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction.

Authors:  Tami Livnat; Yehonatan Weinberger; José A Fernández; Alaa Bashir; Gil Ben-David; Dahlia Palevski; Sarina Levy-Mendelovich; Gili Kenet; Ivan Budnik; Yael Nisgav; John H Griffin; Dov Weinberger
Journal:  Biomolecules       Date:  2021-02-26

2.  Long-term outcomes of intravitreal activated protein C injection for ischemic central retinal vein occlusion: an extension trial.

Authors:  Chikako Hara; Motohiro Kamei; Hirokazu Sakaguchi; Nagakazu Matsumura; Susumu Sakimoto; Mihoko Suzuki; Kentaro Nishida; Yoko Fukushima; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-24       Impact factor: 3.117
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.